Payment overview · 2025
General Payments
$633.14
27 reported records · 15 companies
Healthcare provider profile · identity verified
Robert Martin Marcus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1588631923
Verified facts
What the public records show
CMS Open Payments records show Robert Martin Marcus, M.D. received $633.14 in general payments during 2025 across 27 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $163.04 | 25.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.92 | 11.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.19 | 11.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.01 | 6.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.43 | 6.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.42 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.12 | 6.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.50 | 4.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.91 | 3.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.94 | 3.6% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.41 | 3.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.79 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.95 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.45 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.06 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.14 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $163.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.12 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.63 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 117 |
| Losartan Potassium | Losartan Potassium | 269 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 58 |
| Lisinopril | Lisinopril | 161 | 49 |
| Chlorthalidone | Chlorthalidone | 126 | 38 |
| Omeprazole | Omeprazole | 124 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 32 |
| Simvastatin | Simvastatin | 111 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 17 |
| Metformin Hcl | Metformin Hcl | 84 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 25 |
| Spironolactone | Spironolactone | 74 | 19 |
| Potassium Chloride | Potassium Chloride | 73 | 27 |
| Allopurinol | Allopurinol | 72 | 22 |
| Eliquis | Apixaban | 66 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 20 |
| Trazodone Hcl | Trazodone Hcl | 60 | 22 |
| Ramipril | Ramipril | 58 | 19 |
| Furosemide | Furosemide | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 15 |
| Alprazolam | Alprazolam | 55 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Ezetimibe | Ezetimibe | 50 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Gabapentin | Gabapentin | 47 | 13 |
| Celecoxib | Celecoxib | 44 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Lorazepam | Lorazepam | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 11 |
| Famotidine | Famotidine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Prolia | Denosumab | 13 | 11 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.14 · 27 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, APLENZIN, AREXVY, Auvelity, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, General - Pain Management, KISUNLA, Leqembi, NEXLETOL, NURTEC ODT, OPSUMIT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, UPTRAVI, WELLBUTRIN, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error